



breast cancer
care wa

ANNUAL FINANCIAL REPORT
For the period ended 31 December 2018

Contents	Page
Information Register	1
Directors' Report	2
Directors' Qualifications	6
Statement of Income & Expenditure	8
Statement of Financial Position	9
Statement of Changes in Funds	10
Statement of Cash Flows	11
Notes to the Financial Statements	12
Directors' Declaration	23
Independent Audit Report	24

Information Register

ABN 77 221 238 430

Board of Directors

<i>Role</i>	<i>Name</i>
Chairman	Malcolm Day
Deputy-Chairman	Simon Martin
Director	Dr Corinne Jones
Director	Bonnie Bullock
Director	Ralph Winter
Director	Pauline Gately
Director	Adam Marshall

Registered Office

80 Railway Street
Cottesloe WA 6011

Bankers

National Australia Bank
464 Hay Street
SUBIACO WA 6008

ANZ Bank
1275 Hay Street
WEST PERTH WA 6005

Bendigo Bank
9 Adelaide St
Fremantle WA 6160

Auditors

BDO Audit (WA) Pty Ltd
38 Station Street
SUBIACO WA 6008

Directors' Report

Our directors present this report of Breast Cancer Care WA Inc.

BOARD

The names of each person who has been a director during the period and at the date of the report are:

Name	Date Appointed	Date Ceased
Malcolm Day	2004	Current
Simon Martin	February 19, 2009	Current
Dr Corinne Jones	March 18, 2009	Current
Bonnie Bullock	May 16, 2012	Current
Ralph Winter	May 16, 2012	Current
Pauline Gately	March 19, 2014	Current
Adam Marshall	December 8, 2016	Current

PRINCIPAL ACTIVITIES

The principal activities of Breast Cancer Care WA in the course of the period consisted of providing personalised emotional, practical and financial support and care to people affected by breast cancer and educating the community to increase awareness and early detection of breast cancer.

Support services are offered free of charge and are tailored to a broad range of specific client needs, and our core services include:

- **Breast Care Nurse support:** in the home, at hospital and medical appointments and from our Cottesloe Offices.
- **Counselling support:** 1:1 appointments, couples and family counselling.
- **Financial Assistance:** paying gaps in medical expenses, putting food on the table and paying some expenses such as utilities during hardship.
- **Support Groups:** we run 16 monthly support groups for women in different stages of the disease, different age groups, different locations, and a specific dedicated support group for partners of people with breast cancer.
- **Therapy Groups, Workshops & Retreats:** we run workshops including art and clay therapy, legacy and resilience building, two-day intensive therapy groups dealing with fear and uncertainty, and an annual fly fishing retreat weekend.
- **Education:** we deliver talks in the community to raise awareness on the importance of the early detection of breast cancer, distribute support materials including breast self-examination guides and run health promotion articles in our quarterly newsletter Spirit. We provide individual client education and group client workshops to educate and empower clients living with a new or recurrent or metastatic cancer to better self-manage distress and wellbeing.
- **Referrals and connections:** we work with other organisations and Health Professionals including Breast Clinics, Oncologists, Surgeons, GP's, Breast Care Nurses, Social Workers, the Cancer Council and Breast Cancer Network Australia to refer clients to existing services and broaden their support network.

Emotional Support

Our team of five specialist Breast Care Nurses, four Counsellors, Client Support Coordinator and Support Services Manager play a vital role in providing emotional support and information at various phases across the continuum of care including diagnosis, treatment, rehabilitation, follow-up, survivorship and palliative care.

We continue to experience high demand for our Support Services, and the number of clients to whom we are providing support remains consistent. In 2018 we provided support to 1,093 individual clients (1069 in 2017), with our Breast Care Nurses providing 5932 occasions of service, and our Counsellors providing 6314 occasions of service. Including direct occasions of service provided by our Client Support Coordinator, a total of 13,481 instances of support were provided to our clients and their families.

The challenging economic climate continues to put added financial pressure on our clients, and the demand for financial support remains high. Additionally, the complexity of many client cases has meant that each client requires a wide range of support services, and increased ongoing support.

To meet the specialised needs of those with advanced breast cancer, we have a dedicated Metastatic Breast Care Nurse to best support the unique issues such a diagnosis brings. This specialised support along with increased support groups and workshops through the year has again increased the depth and impact of the support we provide.

Our qualified counsellors provide one on one counselling to clients and their family throughout the metropolitan area and including Mandurah. Telephone counselling is provided to those living in regional WA.

We have expanded our monthly support groups, including additional support groups for those with advanced breast cancer, and the support group for partners of those with breast cancer. Our Counsellors currently facilitate 16 monthly support group meetings, and a quarterly partners' support group throughout the metropolitan area, reaching as far as Mandurah. Studies have identified physical and emotional benefits for those attending support group meetings, hence our investment in providing a wide range of group meetings. The total number of support group meetings held in 2018 was 135.

12 one and two-day workshops and therapy groups were held during the year, dealing with fear and uncertainty, resilience and offering opportunities to participate in creative activities such as art and clay therapy. We also introduced a Legacy workshop to provide specific support for those with a metastatic breast cancer diagnosis. Clients undergo therapy in a group situation and gain from the experience of the counsellors as well as from other members of the group. As with support groups, studies have identified many positive outcomes for attendees, and the feedback received from clients is overwhelmingly positive.

Practical support

Practical Assistance:

Following surgery and during treatment, we provide help with basic living needs including; transport to and from appointments, help with looking after children, shopping, cleaning and gardening.

Information and Referrals:

We operate as an information service and also provide referrals to other agencies for financial counselling, wigs, prosthesis and lymphoedema treatment etc.

Financial Support

A diagnosis of breast cancer can have a serious financial impact, especially if a client is unable to work during treatment. In 2018 we processed 316 financial assistance requests, which included providing 1,401 food and fuel vouchers to put food on the table and enable clients to get to medical and treatment appointments.

Education Programs

Early detection of breast cancer is vital to ensure the best chance of successful treatment. Our education and awareness initiatives seek to teach people of all ages to be breast aware and develop good breast health habits. Additionally, our Nurses and Counsellors provide education support to our clients, their families and carers, to equip them with information and experiences that support their quality of life.

As a West Australian charity supporting people diagnosed with breast cancer, along with their family members and carers, at Breast Cancer Care WA we operate in the spirit of collaboration. This is evidenced in our participation as a founding member charity of the Cancer Wellness Centre and our work with many other great organisations to provide the best and most comprehensive support service possible to people affected by breast cancer.

Results from Operations

Operations Review

A deficit of \$ 421,360 was made during the course of January to December 2018 compared to the budgeted deficit of \$ 526,658.

The application of costs for the period ended 31 December 2018 was as follows:

Employment Costs:	48%
Operational Cost:	10%
Administration Costs:	3%
Fundraising Costs:	15%
Growth Initiatives:	23%
Changes in Fair Value:	<u>1%</u>
Total Applied Funds	100%

Further details of Breast Cancer Care WA Inc. results can be found in notes 3 and 4 to the financial statements.

As an organisation dedicated to providing personalised support services tailored to the needs of each individual client, our greatest expense and our greatest asset is our Team, without whom our Support Services would not be possible.

Expenses are managed tightly to budget and savings made wherever possible to minimise the impact of a challenging fundraising period, and position the organisation for a strong start to 2019.

In 2018, as part of our continuing response to the challenging economic climate, we continued with our growth initiatives strategy to encourage donors to make regular monthly contributions so that we can be assured of sustainable income to fund our vital services. This strategy requires significant upfront costs, which we recognised would be high at the outset, and we carefully weighed our decision against the expected benefit of the future income streams and the resources available to us. Two and a half years into the program, targets are being met and all key indicators continue to perform as originally planned. We are confident that the implementation of our growth initiatives strategy was and remains a sound decision.

The reported deficit in operations of \$421,360 (\$105,298 better than budgeted) is the result of our commitment to continuing our supportive care service delivery at current levels. It is made possible due to the sound financial management and planning by our Board of Directors over many years, who had set aside a sustainability fund, which we have been able to draw on during this challenging economic period. The continuing success of our growth initiatives strategy will see this deficit diminish in the coming years.

With over 1,700 people in WA diagnosed with breast cancer each year, it is vital that we not only invest in delivering support services today, but also in creating sustainable income sources to allow us to be here for those affected in the future.

Cash and invested funds at 31 December 2018 total **\$1,676,416** (31 December 2017 **\$2,044,552**).

STRATEGIC HORIZON

We continue to endeavour to meet and surpass our goals in providing support services for all Western Australians whose lives have been affected by breast cancer.

Signed in accordance with a resolution of the directors
For and on behalf of the Board:



Malcolm Day
Director and Chairman
29 April 2019



Simon Martin
Director and Vice-Chairman
29 April 2019

Directors' Qualifications

Name	Qualifications	Experience	Special responsibilities
Malcolm Day	Bachelor of Applied Science Surveying and Mapping, Licensed Surveyor	<p>Previously employed as a Senior Civil Engineer. Founder and Owner of Adultshop.com Ltd (after privatising the business in 2010), non-executive Director of European Lithium Ltd (listed on the Australian, German and Austrian Stock Exchanges), previously a member of the Australian Institute of Company Directors.</p> <p>Managing Director of Delecta Ltd (listed on the Australian Stock Exchange).</p> <p>Founder of the annual Boobalicious Ball.</p>	Chairman Investment Committee
Simon Martin	BComm, CA GAICD	<p>An executive with over 20 years' experience across all facets of business management. Simon's previous roles include General Manager for Network Ten Perth and CEO for Cystic Fibrosis Australia.</p> <p>Simon is currently the Chief Operating Officer for WA Primary Health Alliance.</p>	Vice Chairman Investment Committee
Dr Corinne Jones	MBBS (UWA) FRACS FRCS	Full time, private Breast, Thyroid & Parathyroid Surgeon, working and consulting at St John of God Hospital in Subiaco.	Professional Recognition, Personalised Care
Bonnie Bullock	BArts. Member of PRIA.	Director of Saranac PR. Bonnie has worked in public relations for over 20 years spanning the USA, Sydney and Perth. Bonnie has extensive experience in media relations, issues + crisis management and corporate profiling.	Marketing and Communications
Ralph Winter	BComm, GAICD	Commercial Director/Joint Company Secretary of Moho Minerals Ltd; Ralph has worked for 13 years in various industries (mostly mining) with extensive commercial experience and a strong focus on finance acquisition, public and investor relations, business management and marketing.	Investment Committee
Pauline Gately	BA Hons Economics, PG Dip Acc	Non-Executive Director and Audit Committee Chair of Ardiden Ltd, a boutique ASX listed mining company. Pauline is also former Chairman of ASX and SGX listed Alliance Mineral Assets Ltd, and brings more than 20 years of investment banking experience as an investment strategist, economist and asset manager at the most senior level in the Asia Pacific Region.	Investment Committee

Name	Qualifications	Experience	Special responsibilities
Adam Marshall	2:1 BA Economics, Goldsmiths College, University of London	<p>Adam is the Chief Executive Officer of Marketforce, a member of the Clemenger BBDO Network. He has over twenty years media experience and has worked in the UK and Asian markets. He is a regular commentator on media matters in the broader media and has lectured on advertising and marketing at each of Perth's universities and at AdSchool.</p> <p>Adam has previously been Chairperson of the Oasis Committee the WA advertising industry's charity association and is a board member of charity FTT, a group dedicated to raising funds for disabled athletes.</p>	Marketing and Communications

Statement of Income and Expenditure

FOR THE PERIOD ENDED 31 DECEMBER 2018

	Notes	31 Dec 2018	31 Dec 2017
INCOME		\$	\$
Fundraising Income	4a	3,062,802	2,557,213
Investment Income	4b	66,112	180,109
Total Revenue & Other Income		<u>3,128,914</u>	<u>2,737,322</u>
EXPENDITURE			
<i>Operational</i>		(356,947)	(288,585)
<i>Fundraising</i>		(528,695)	(312,934)
<i>Administration</i>		(120,108)	(203,540)
<i>Employment</i>	5	(1,690,685)	(1,489,713)
<i>Growth Initiatives</i>		(806,883)	(794,272)
<i>Changes in Fair Value of Financial Assets</i>	9	(46,956)	-
Total		<u>(3,550,274)</u>	<u>(3,089,044)</u>
Net surplus (loss) for the period		<u>(421,360)</u>	<u>(351,722)</u>
Net changes in fair value of available for sale financial assets	9	-	942
Total Comprehensive Income/ (Expense) for the period		<u>(421,360)</u>	<u>(350,780)</u>

The statement of income and expenditure is to be read in conjunction with the attached notes.

Statement of Financial Position

	Notes	31 Dec 2018 \$	31 Dec 2017 \$
ASSETS			
Current Assets			
Cash and cash equivalents	6	632,211	935,190
Trade and other receivables	7	88,789	95,903
Prepayments		29,331	27,898
Total Current Assets		750,331	1,058,991
Non-Current Assets			
Plant and equipment	8	108,714	138,588
Financial Assets	9	1,044,205	1,109,363
Total Non-Current Assets		1,152,919	1,247,951
TOTAL ASSETS		1,903,250	2,306,942
LIABILITIES			
Current Liabilities			
Trade and other payables	10	127,415	134,449
Provisions	11	60,891	53,795
Total Current Liabilities		188,306	188,244
Non-Current Liabilities			
Provisions	11	23,270	5,664
Total Non-Current Liabilities		23,270	5,664
TOTAL LIABILITIES		211,576	193,908
NET ASSETS		1,691,674	2,113,034
FUNDS			
General Funds		1,691,674	1,979,719
Unrealised Gain Reserve	2	-	133,315
TOTAL FUNDS		1,691,674	2,113,034

The statement of financial position is to be read in conjunction with the attached notes.

Statement of Changes in Funds

	Notes	Unrealised Gain Reserve	General Funds	Total Funds
		\$	\$	\$
Balance at 1 January 2017		132,373	2,331,441	2,463,814
Net surplus		-	(351,722)	(351,722)
Other Comprehensive Income		942	-	942
Balance at 31 December 2017		133,315	1,979,719	2,113,034
Balance at 1 January 2018		133,315	1,979,719	2,113,034
Adjustment on adoption of AASB 9	2	(133,315)	133,315	-
Adjusted balance at 1 January 2018		-	2,113,034	2,113,034
Net surplus		-	(421,360)	(421,360)
Balance at 31 December 2018		-	1,691,674	1,691,674

The statement of changes of funds is to be read in conjunction with the attached notes.

Statement of Cash Flows

	Notes	31 Dec 2018	31 Dec 2017
		\$	\$
<i>Cash flows from operating activities</i>			
Receipts from:			
Fundraising Income		3,100,367	2,578,595
Investment Income		63,426	182,051
Payments to suppliers & employees		(3,583,035)	(3,231,962)
<i>Cash flows from other operating activities</i>		118,808	-
<i>Net cash from/(used in) operating activities</i>	13	<u>(300,434)</u>	<u>(471,316)</u>
 <i>Cash flows from investing activities</i>			
Purchase of property plant and equipment		(8,793)	(15,097)
Purchase of Financial Assets		(126,768)	(81,971)
Sale of Financial Assets		133,016	871,781
<i>Net cash from/(used in) investing activities</i>		<u>(2,545)</u>	<u>774,713</u>
 <i>Net increase/(decrease) in cash and cash equivalents</i>		<u>(302,979)</u>	<u>303,397</u>
 Cash and cash equivalents at the beginning of the period		935,190	631,793
Cash and cash equivalents at the end of the period	6	<u>632,211</u>	<u>935,190</u>

The statement of cash flows is to be read in conjunction with the attached notes.

Notes to the Financial Statements

31 December 2018

1. CORPORATE INFORMATION

The financial statements of the not-for-profit company, Breast Cancer Care WA Inc for the period ended 31 December 2018 were authorised for issue in accordance with a resolution of the directors on 29 April 2018.

Breast Cancer Care WA Inc. is an incorporated association operating exclusively in Australia. The nature of the entity's operations and principal activities are described in the director's report.

2. CHANGES IN ACCOUNTING POLICIES

AASB 9 Financial Instruments

AASB 9 Financial Instruments replaces AASB 139 Financial Instruments: Recognitions and Measurement. It makes major changes to the previous guidance on the classification and measurement of financial assets and introduces an "expected credit loss" model for impairment of financial assets.

When adopting AASB 9, BCCWA has applied transitional relief and opted not to restate prior periods. Differences arising from the adoption of AASB 9 in relation to classification, measurement and impairment are recognised in opening retained earnings as at 1 January 2018.

The adoption of AASB 9 has impacted the classification and measurement of the Financial instruments as follows:

Listed equity investments – Available for Sale Financial assets under AASB 139 included listed equity investments of \$ 1,109,363 at 31 December 2017. These were reclassified to Financial Assets accounted for at fair value through profit or loss (FVPL) under AASB 9. Consequently, an amount of \$ 133,315 was transferred from the Unrealised Gain Reserve to the Retained Earnings on 1 January 2018.

Changes in Fair Value of Financial Assets – In the prior year, the net movement in Fair Value was recognised in Other Comprehensive Income. Pursuant to the implementation of AASB 9 and Breast Cancer Care's election to classify and measure the investments at Fair Value through Profit and Loss, the net decrease in fair value of \$ 46,956 was recognised as part of the Net Operating income in the current period.

The only impairment methodology under this standard uses more forward looking information to measure the impairment under the 'Expected Credit Losses (ECL) model. Instruments within the scope of this model include financial assets measured at amortised cost and FVOCI. No impairment was recognized in the current period since the financial assets are measured at FVPL.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of preparation

These general purpose financial statements have been prepared in accordance with the requirements of the Associations Incorporations Act [WA], Australian Accounting Standards – Reduced Disclosure Requirements, other authoritative pronouncements of the Australian Standards Board, Urgent Issues Group Interpretations and the ACNC Act 2012.

The directors have determined that Breast Cancer Care WA Inc is permitted to apply the Tier 2 reporting requirements (Australia Accounting Standards – Reduced Disclosure Requirements) as set out in AASB 1053 Application of tiers of Australian Accounting Standards because it is a not-for-profit private sector entity that does not have public accountability. The authorisation for the issue of these accounts is in accordance with a resolution of the directors on 29 April 2019.

Historical Cost Accounting.

The financial statements have been prepared on the basis of historical cost.

Functional Currency.

The financial report is presented in Breast Cancer Care WA Inc.'s functional currency which is the Australian dollar.

(b) Significant accounting judgements, estimates and assumptions

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and other various factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

Significant accounting judgements

The entity has entered into leases of premises and office equipment. Management has determined that all of the risks and rewards of ownership of these premises and equipment remain with the lessor and has therefore classified the leases as operating leases.

Significant accounting estimates and assumptions

The key estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of certain assets and liabilities within the next annual reporting period are:

Provisions for employee benefits

Provisions for employee benefits payable after 12 months from the reporting date are based on future wage and salary levels, experience of employee departures and periods of service, as discussed in Note 3(l).

The amount of these provisions would change should any of these factors change in the next 12 months.

(c) Revenue recognition

Revenue is recognised to the extent it is probable that the economic benefits will flow to Breast Cancer Care WA and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

(i) Donations & Growth Initiatives

Donations and sponsorships are recognised on a receipts basis when the amount can be measured reliably.

(ii) Investment income

Investment income comprises interest, dividends, trust distributions and realised gains on investments. Interest income is recognised as it accrues, using the effective interest method. Dividends and distributions from entities are recognised when the right to receive the income has been established.

(iii) Sale of Goods

Revenue is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer and the costs incurred or to be incurred in respect of the transaction can be measured reliably. Risks and rewards of ownership are considered passed to the buyer at the time of delivery of the goods to the customer.

(iv) Sponsorships & Grants

Sponsorships and grants are recognised when there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognised as income over the periods necessary to match the grant on a systematic basis to the costs it is intended to compensate.

(d) Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to a particular category they have been allocated to activities on a basis consistent with use of the resources.

Fundraising costs are those incurred in seeking voluntary contributions by donation and do not include costs of disseminating information relating to the activities carried on by the entity. Costs incurred in obtaining regular donations are expensed in full when the donor is registered to make a future donation. These costs have been disclosed as growth initiatives in the Financial Statements.

Operational costs are those costs directly incurred in supporting the objects of the entity.

Administration costs are those costs incurred in connection with administration of the entity and compliance with constitutional and statutory requirements.

Employment costs have been incurred in order to service the operational activities of the entity, predominantly the professional team to deliver support services to people affected by breast cancer, administer those services and assist with fundraising activities and the coordination of volunteers. An allocation of employment costs to each category is provided at note 5.

(e) Cash and cash equivalents

Cash and short-term deposits in the statement of financial position is comprised of cash at bank and in hand, and short-term deposits with an original maturity of six months or less.

For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts.

(f) Trade and other receivables

Trade receivables, which generally have 30-90 day terms, are recognised and carried at original invoice amount less an allowance for any uncollectible amounts.

Breast Cancer care applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. Bad debts are written off when identified.

Other receivables include donations which are accrued when it is probable that funds will be received and can be reliably measured.

(g) Plant and Equipment

Plant and equipment is stated at cost less accumulated depreciation and any accumulated impairment losses.

Depreciation is calculated on a straight-line basis over the estimated useful life of the assets as follows:

Plant and equipment 3 to 5 years
Motor Vehicles 5 years

The assets' residual values, useful lives and amortisation methods are reviewed, and adjusted if appropriate, at each financial period.

Impairment

The carrying values of plant and equipment are reviewed for impairment at each reporting date, with recoverable amount being estimated when events or changes in circumstances indicate that the carrying value may be impaired.

The recoverable amount of plant and equipment is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

For an asset that does not generate largely independent cash inflows, recoverable amount is determined for the cash-generating unit to which the asset belongs, unless the asset's value in use can be estimated to be close to its fair value.

Impairment exists when the carrying value of an asset or cash-generating units exceeds its estimated recoverable amount. The asset or cash-generating unit is then written down to its recoverable amount.

(h) Financial assets

Recognition, initial measurement and derecognition

Financial assets are recognised when Breast Cancer Care becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets are described below.

The fair value of investments that are actively traded in organised financial markets is determined by reference to quoted market bid prices at the close of business on the reporting date. For investments with no active market, fair value is determined using valuation techniques. Such techniques include using recent arm's length market transactions, reference to the current market value of another instrument that is substantially the same, discounted cash flow analysis and option pricing mode.

Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred.

Classification of financial assets

Classifications are determined by both:

- The business model for managing the financial asset
- The contractual cash flow characteristics of the financial assets

Classification and subsequent measurement of financial assets

Under AASB 9, the basis on which the financial assets are measured is relevant to the way they are classified. The identification can be initiated by an assessment of the following critical issues in relation to these assets:

- The objective of the entity's business model is to hold these assets only to collect cash flows, or to collect cash flows and to sell ("The Business Model Test") and
- The contractual cash flows of the assets give rise to contractual payments that are solely payments of principal and interest ("SPPI Test")

Both of these tests must to be met in order to classify and measure the asset at:

- Amortised Cost
- Equity instruments at Fair Value through Other Comprehensive Income (FVOCI)

Failing these tests requires the assets to be classed and measured at Fair Value through Profit & Loss (FVPL).

Financial assets at fair value through profit or loss (FVPL)

Financial assets that are held within a different business model other than 'hold to collect' or 'hold to collect and sell' are categorised at fair value through profit and loss. Further, irrespective of business model financial assets whose contractual cash flows are not solely payments of principal and interest are accounted for at FVPL.

Given that the business model and contractual cash flows of the assets differ from the above tests, Breast Cancer Care has categorised the equity investments on hand at fair value through profit and loss from 1 January 2018.

(i) Impairment of financial assets at fair value through profit and loss

Breast Cancer Care follows the guidance of AASB 9 Financial Instruments to determine when a financial asset is impaired. The only impairment methodology under this standard uses more forward looking information to measure the impairment under the 'Expected Credit Losses (ECL) model. Instruments within the scope of this model include financial assets measured at amortised cost and FVOCI.

(j) Trade and other payables

Trade payables and other payables are carried at amortised costs and represent liabilities for goods and services provided to Breast Cancer Care WA prior to the end of the period that are unpaid and arise when Breast Cancer Care WA becomes obliged to make future payments in respect of the purchase of these goods and services.

(k) Provisions

Provisions are recognised when Breast Cancer Care WA has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

When Breast Cancer Care WA expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of comprehensive income net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a pre-tax rate that reflects the risks specific to the liability. When discounting is used, the increase in the provisions due to the passage of time is recognised as a borrowing cost.

(l) Employee entitlements

(i) Wages, salaries, annual leave and sick leave

Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave expected to be settled within 12 months of the reporting date are recognised in other payables in respect of employees' services up to the reporting date. They are measured at the amounts expected to be paid when the liabilities are settled. Liabilities for non-accumulating sick leave are recognised when the leave is taken and are measured at the rates paid or payable.

(ii) Long service leave

The liability for long service leave is recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method.

Consideration is given to the expected future salaries and wage levels, experience of employee departures and periods of service.

(m) Leases

Operating lease payments are recognised as an expense in the statement of comprehensive income on a straight-line basis over the lease term.

(n) Income tax

Breast Cancer Care WA Inc. is exempt from the payment of income tax under the provisions of Section 50-45 of the Income Tax Assessment Act 1997. The entity holds deductible gift recipient status.

(o) Other taxes

Revenues, expenses and assets are recognised net of the amount of GST except:

- when the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
- receivables and payables, which are stated with the amount of GST included.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement of financial position.

Cash flows are included in the Statement of Cash Flows on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to, the taxation authority are classified as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the taxation authority.

(p) New Standards and Interpretations not yet adopted

The following standards, amendments to standards and interpretations have been identified as those that may significantly impact Breast Cancer Care WA in the period of initial application.

Standard	Effective Date	Impact for Breast Cancer Care WA (BCCWA)
AASB 1058 Income of Not-for-Profit Entities	Annual reporting periods commencing on or after 1 January 2019.	<p>Under AASB 1058, the timing of income recognition will depend on whether a transaction gives rise to a performance obligation, liability or contribution by owners.</p> <p>Where BCCWA receives an asset for significantly less than its fair value principally to enable BCCWA to further its objectives, it will recognise the asset in accordance with the relevant standard. BCCWA will then consider the relevant accounting standard that applies to the other side of the entry (called 'related amounts').</p> <p>The difference (if any) between the consideration transferred for the asset and the fair value of the asset received after recording any 'related amounts' is recognised as income.</p> <p>BCCWA has yet to quantify the impact of this standard but recognises that it may have application to the accounting treatment of lease liabilities, financial instruments and contributions by owners and volunteers.</p>
AASB 16 Leases	Annual reporting periods commencing on or after 1 January 2019.	<p>AASB 16 introduces a single lessee accounting model and requires a lessee to recognise assets and liabilities for all leases with a term of more than 12 months, unless the underlying asset is of low value.</p> <p>Under this standard BCCWA is required to recognise a right-of-use asset representing its right to use the underlying leased asset and a lease liability representing its obligations to make lease payments.</p> <p>BCCWA has yet to quantify the impact of this standard.</p>

	31 Dec 2018	31 Dec 2017
	\$	\$
4. INCOME		
(a) Fundraising Income:		
Donations & Growth Initiatives	2,736,827	2,349,880
Sponsorships and grants	325,975	207,333
	<u>3,062,802</u>	<u>2,557,213</u>
(b) Investment Income		
Interest income	9,935	5,679
Other investment income	68,131	74,360
Net gain/(loss) on disposal of Financial Assets	(11,954)	100,070
	<u>66,112</u>	<u>180,109</u>

5. EMPLOYMENT

Operational	(923,443)	(767,549)
Fundraising	(545,855)	(437,177)
Administrative	(158,372)	(191,829)
Growth Initiatives	(63,015)	(93,158)
	<u>(1,690,685)</u>	<u>(1,489,713)</u>

	31 Dec 2018	31 Dec 2017
	\$	\$
6. CASH AND CASH EQUIVALENTS		
Cash at bank and in hand	422,481	99,061
Short-term deposits	209,730	836,129
	<u>632,211</u>	<u>935,190</u>

Cash at bank earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods of between one day and six months, depending on the immediate cash requirements of Breast Cancer Care WA, and earn interest at the respective short-term deposit rates.

	31 Dec 2018	31 Dec 2017
	\$	\$
7. TRADE AND OTHER RECEIVABLES		
Pledges Receivable	53,819	41,919
Net goods & services tax receivable	13,421	27,965
Other receivables	21,549	26,019
	<u>88,789</u>	<u>95,903</u>

Trade receivables, which generally have 30-90 day terms, are recognised and carried at original invoice amount less an allowance for any uncollectible amounts. Breast Cancer care applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. Bad debts are written off when identified.

8. PLANT AND EQUIPMENT

	Furniture & Fixtures	Office Equipment	Trademarks and Licences	Total
	\$	\$	\$	\$
COST OR FAIR VALUE				
At 31 December 2017	125,706	99,657	510	225,873
Additions	-	8,793	-	8,793
Disposals	-	-	-	-
At 31 December 2018	125,706	108,450	510	234,666
ACCUMULATED DEPRECIATION				
At 31 December 2017	28,277	59,008	-	87,285
Depreciation charge for the period	9,437	29,230	-	38,667
Disposals	-	-	-	-
At 31 December 2018	37,714	88,238	-	125,952
NET CARRYING AMOUNT				
At 31 December 2017	97,429	40,649	510	138,588
At 31 December 2018	87,992	20,212	510	108,714

9. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT & LOSS (FVPL) - (NON CURRENT)

Listed investments at fair value in:

	31 Dec 2018	31 Dec 2017
	\$	\$
Fixed Interest Investments	274,886	249,017
Equity Investments	578,099	608,326
Alternative Investments	191,220	252,020
	1,044,205	1,109,363

Movement in financial assets at FVPL

	31 Dec 2018	31 Dec 2017
Beginning balance	1,109,363	1,798,160
Purchases	126,768	81,972
Net disposal of Financial Assets	(144,970)	(771,711)
Changes in Fair Market Value	(46,956)	942

Balance at the end of the period

1,044,205 **1,109,363**

All Shares have no fixed maturity date or coupon rate.

Fixed-interest-securities include corporate bonds, convertible notes and hybrid securities which have coupon rates varying from 2 per cent to 6 per cent and maturity dates ranging from November 2020 to April 2075. The market value of these securities fluctuates from time to time.

	31 Dec 2018	31 Dec 2017
	\$	\$
10. TRADE AND OTHER PAYABLES (CURRENT)		
Visa Cards	6,580	7,121
Trade Creditors	44,717	55,181
Other Creditors	23,947	21,863
Accruals	52,171	50,284
	<u>127,415</u>	<u>134,449</u>

Trade and other payables are carried at amortised costs and represent liabilities for goods and services provided to Breast Cancer Care WA prior to the end of the period that are unpaid and arise when Breast Cancer Care WA becomes obliged to make future payments in respect of the purchase of these goods and services.

	31 Dec 2018	31 Dec 2017
	\$	\$
11. PROVISIONS		
Current		
Employee entitlements – annual leave	60,891	53,795
	<u>60,891</u>	<u>53,795</u>
Non – Current		
Employee entitlements – long service leave	23,270	5,664
	<u>23,270</u>	<u>5,664</u>

	31 Dec 2018	31 Dec 2017
	\$	\$
12. OPERATING LEASES		

Non - cancellable operating leases contracted for but not capitalised in the financial statements.

Payable - Minimum Lease Payment		
Not later than 12 months	30,000	30,000
Between 12 months and 5 years	120,000	120,000
Greater than 5 years	22,500	52,500
	<u>172,500</u>	<u>202,500</u>

13. RECONCILIATION OF NET SURPLUS FOR THE PERIOD TO NET CASH FLOW FROM OPERATIONS

	Note	31 Dec 2018	31 Dec 2017
		\$	\$
Net Surplus/(loss) for the period		(421,360)	(351,722)
Depreciation	8	38,667	30,889
Changes in Fair Value of Financial Assets	9	46,956	-
Net loss on disposal of Financial Assets		11,954	(100,070)
<i>(Increase)/Decrease in Assets</i>			
Receivables		7,114	29,085
Prepayments		(1,433)	(14,351)
<i>Increase/(Decrease) in Liabilities</i>			
Trade creditors and accruals		(7,034)	(34,374)
Provision for employee benefits		24,702	(30,773)
Net cash inflow from/(used in) operating activities		<u>(300,434)</u>	<u>(471,316)</u>

14. RELATED PARTIES AND RELATED PARTY TRANSACTIONS

(a) Directors' compensation

The directors act in an honorary capacity and receive no compensation for their services.

(b) Key management personnel

The compensation paid to those having authority for planning, directing and controlling the entity's activities, directly or indirectly (other than directors), during the year:

	31 Dec 2018	31 Dec 2017
	\$	\$
Short - term employment benefits	376,026	297,372

15. AUDITOR'S REMUNERATION

Amounts received or due and receivable by auditors BDO Audit (WA) Pty Ltd of Breast Cancer Care WA Inc. for:

	31 Dec 2018	31 Dec 2017
	\$	\$
- an audit of the financial statements	3,500	3,500

16. EVENTS AFTER THE REPORTING DATE

No matter or circumstance has arisen that has significantly affected, or may significantly affect, the operations of Breast Cancer Care WA Inc., the results of those operations or the state of affairs of Breast Cancer Care WA Inc. in subsequent years.

17. CONTINGENT ASSET AND CONTINGENT LIABILITIES

The directors are not aware of any Contingent Assets and Contingent Liabilities that existed as of 31 December 2018.

Directors' Declaration

The directors of Breast Cancer Care WA Inc declare that:

1. The financial statements, comprising the statement of income and expenditure, statement of financial position, statement of cash flows, statement of changes in fund, and accompanying notes, are in accordance with the ACNC Act 2012 and:
 - a. comply with Australian Accounting Standards – Reduced Disclosure Requirements and the ACNC Regulations 2014; and
 - b. give a true and fair view of the entity's financial position as at 31 December 2018 and of its performance for the period ended on that date.

2. In the directors'/responsible entity's opinion, there are reasonable grounds to believe that the entity will be able to pay its debts as and when they become due and payable.

On behalf of the directors by:



Malcolm Day
Director and Chairman
Perth, 29 April 2019



Simon Martin
Director and Vice-Chairman
Perth, 29 April 2019

INDEPENDENT AUDITOR'S REPORT

To the members of Breast Cancer Care WA Inc.

Report on the Audit of the Financial Report

Qualified Opinion

We have audited the financial report of Breast Cancer Care WA Inc., which comprises the statement of financial position as at 31 December 2018, the statement of income and expenditure, the statement of changes in funds and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the directors' declaration.

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial report of Breast Cancer Care WA Inc. is prepared in accordance with Division 60 of the Australian Charities and Not-for-profits Commission Act 2012 including:

- (a) giving a true and fair view of the registered entity's financial position as at 31 December 2018 and of its financial performance for the period ended; and
- (b) complying with Australian Accounting Standards - Reduced Disclosure Requirements and Division 60 of the Australian Charities and Not-for-profits Commission Regulation 2013.

Basis for Qualified Opinion

Fundraising income (which includes Cash donations, fundraising programs, event income and sponsorships and grants) are a significant source of revenue for Breast Cancer Care WA Inc. Breast Cancer Care WA Inc. has determined that it is impracticable to establish control over the collection of fundraising income prior to entry into its financial records. Accordingly, as the evidence available to us regarding fundraising income from this source was limited, our audit procedures had to be restricted to the amounts recorded in the financial records, amounting to \$2,736,827. We therefore are unable to express an opinion whether the fundraising income Breast Cancer Care WA Inc. recorded are complete. Consequently, we were unable to determine whether any adjustments to these amounts were necessary.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the Financial Report section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the Australian Charities and Not-for-profits Commission Act 2012 (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.



Other information

The directors of the registered entity are responsible for the other information. The other information obtained at the date of this auditor's report includes the registered entity's annual report for the year ended 31 December 2018, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of responsible entities for the Financial Report

The directors of the registered entity are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the ACNC Act, and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors of the registered entity are responsible for assessing the registered entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intends to liquidate the registered entity or to cease operations, or has no realistic alternative but to do so.

The directors of the registered entity are responsible for overseeing the registered entity's financial reporting process.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.



A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf

This description forms part of our auditor's report.

BDO Audit (WA) Pty Ltd

BDO

A handwritten signature in black ink, appearing to read 'J Prue'.

Jarrad Prue

Director

Perth, 29 April 2019